10-Q: Doximity Q1 Revenue Jumps 15% to $145.9M, Net Income Up 29%

Doximity, the leading digital platform for U.S. medical professionals, reported strong first-quarter results with a 15% revenue increase and a 29% rise in net income, alongside a strategic acquisition and ongoing share repurchases.

Summary

• Revenue for the three months ended June 30, 2025, increased by 15% to $145.9 million, up from $126.7 million in the prior year period.
• Net income grew by 29% to $53.3 million for the quarter, compared to $41.4 million in the same period last year.
• Diluted net income per share was $0.27, an increase from $0.21 in the prior year.
• Adjusted EBITDA rose 21% to $79.8 million, with an adjusted EBITDA margin of 55%, up from 52% year-over-year.
• Free cash flow significantly increased by 52% to $60.1 million, compared to $39.5 million in the previous year.
• The company completed the acquisition of Pathway Medical Inc., an AI-based medical knowledge platform, for $26 million in cash in July 2025.
• An additional $37 million in restricted stock unit awards were issued to certain individuals joining the company from Pathway Medical Inc.
• The board authorized a $500 million share repurchase program on May 1, 2024, under which $198.3 million has been utilized as of June 30, 2025, with $301.7 million remaining.
• Legal proceedings, including securities litigation and five shareholder derivative lawsuits, are ongoing, alleging violations of securities law, breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste against certain directors and officers.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant growth in revenue, net income, adjusted EBITDA, and free cash flow. Strategic moves like the Pathway Medical acquisition and ongoing share repurchases are positive. While legal proceedings introduce uncertainty, the current financial strength and strategic direction suggest a positive outlook.

Positives

• Total revenue increased by 15% to $145.9 million for the three months ended June 30, 2025, driven by a $17.9 million increase in subscription revenue.
• Net income grew by 29% to $53.3 million, demonstrating strong profitability.
• Adjusted EBITDA increased by 21% to $79.8 million, with an improved margin of 55%.
• Free cash flow surged by 52% to $60.1 million, indicating robust cash generation.
• Gross margin remained strong and consistent at 89% for both periods.
• Other income, net, increased by 35% to $9.6 million, primarily due to higher interest income from cash equivalents and marketable securities.
• The company continues its share repurchase program, with $301.7 million remaining authorized, signaling confidence in its valuation and returning capital to shareholders.
• Strategic acquisition of Pathway Medical Inc. enhances AI capabilities and product offerings.

Negatives

• Cash and cash equivalents decreased from $209.6 million as of March 31, 2025, to $137.3 million as of June 30, 2025, primarily due to significant share repurchases and payments for contingent consideration.
• Operating expenses increased by 12.7% year-over-year, with general and administrative expenses seeing a 34% rise, partly due to increased legal and accounting expenses.
• Ongoing securities litigation and five shareholder derivative lawsuits against the company and certain directors/officers create uncertainty and potential financial liabilities.

Risks

• Uncertainty regarding future revenue, expenses, and other operating results.
• Challenges in managing future growth, including acquiring and retaining members and customers.
• Ability to achieve or maintain profitability amidst increasing operating expenses.
• Potential for significant costs and adverse outcomes from ongoing legal proceedings related to user count and engagement rates disclosure.
• Risks associated with maintaining, protecting, and enhancing intellectual property rights.
• Challenges in maintaining data privacy and data security in a rapidly evolving technological landscape.
• Impact of uncertainty in the current economic environment on business operations and customer spending.
• Intense competition from existing competitors and new market entrants.
• Increased expenses associated with being a publicly-traded company, including compliance, legal, audit, and consulting fees.
• Potential inability to raise additional capital on acceptable terms if required for future acquisitions or investments.
• Risks related to the Class A common stock and the dual-class common stock structure.

Future Outlook

The company believes its existing cash and cash equivalents and marketable securities will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months. Gross margin is expected to remain relatively steady over the near term, with quarterly fluctuations. Research and development expenses, sales and marketing expenses, and general and administrative expenses are all expected to increase on an absolute dollar basis as the company continues to grow its platform and product offerings and incurs public company compliance costs.

Management Comments

• Our mission is to help every physician be more productive and provide better care for their patients.
• We are physicians-first, putting technology to work for doctors instead of the other way around.
• That guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians and their colleagues.

Industry Context

Doximity operates as the leading digital platform for U.S. medical professionals, with over 80% of U.S. physicians as members. Its business model is centered on providing Marketing, Hiring, and Workflow Solutions to pharmaceutical companies and health systems, leveraging its extensive network. The recent acquisition of Pathway Medical Inc., an AI-based medical knowledge platform, indicates a strategic move to enhance its AI capabilities and further integrate advanced technology into its offerings, aligning with broader industry trends towards digital transformation and AI adoption in healthcare.

Management Changes

Corporate Governance

Legal Proceedings

• Securities litigation, captioned In re Doximity, Inc. Securities Litigation, No. 5:24-cv-02281 (N.D. Cal.), filed in April 2024, on behalf of a putative class of investors from June 24, 2021, and August 8, 2023, against the company and its CEO, related to disclosure of user count and engagement rates. The lawsuit is currently in the discovery phase.
• Five shareholder derivative lawsuits, including In re Doximity, Inc. Stockholder Derivative Litigation, No. 5:24-cv-02801 (N.D. Cal.), Guttman v. Tangney, et al,. 1:24-cv-01387 (D. Del), Wong v. Tangney, et al., No. 1:25-cv-750 (D. Del.), and Stern v. Tangney, et al., No. 2025-0661 (Del. Ch.), asserting claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste against certain directors and officers. The company is unable to predict the outcome or estimate the range of loss.

Related Party Transactions

• A Consulting Agreement was entered into with Nate Gross, an Advisor (and co-founder), effective June 17, 2025, providing for continued equity vesting of 9,627 shares for July, August, and September 2025 in exchange for general advisory services.
• A warrant was issued to U.S. News & World Report, L.P. in October 2021 to purchase 516,000 shares of Class A common stock, with 28,667 shares exercised during the quarter and 250,833 shares outstanding as of June 30, 2025.

Stakeholder Impact

• Shareholders benefit from strong financial performance, including increased net income and free cash flow, as well as the ongoing share repurchase program. However, they face potential risks from the ongoing securities litigation and derivative lawsuits.
• Employees, particularly those joining from Pathway Medical Inc., benefit from new restricted stock unit awards. Stock-based compensation remains a significant component of overall compensation.
• Customers benefit from enhanced platform capabilities through continued R&D investment and the acquisition of AI-based medical knowledge platform, Pathway Medical Inc.
• Management and directors are subject to legal scrutiny due to the ongoing lawsuits, which allege breaches of fiduciary duties and other misconduct.

Next Steps

• Integration of Pathway Medical Inc. to enhance AI-based medical knowledge platform.
• Continued investment in cloud infrastructure and customer support organizations to sustain business growth.
• Ongoing investment in research and development to expand platform and product offerings.
• Execution of the remaining $301.7 million under the authorized share repurchase program.
• Evaluation of the impact of the new Tax Act on future cash taxes.

Key Dates

Recommendation

Doximity's strong financial performance, marked by double-digit revenue, net income, and free cash flow growth, demonstrates robust operational execution and market leadership. The consistent gross margin and increasing adjusted EBITDA margin highlight efficient business management. The strategic acquisition of Pathway Medical Inc. strengthens the company's competitive position in AI-driven healthcare solutions. Furthermore, the ongoing share repurchase program signals management's confidence in the company's intrinsic value and commitment to returning capital to shareholders. While the legal proceedings introduce a degree of uncertainty, the company's fundamental strength, growth trajectory, and strategic initiatives outweigh these risks, making it an attractive investment opportunity.

Keywords

Doximity, DOCS, Healthcare Technology, Digital Health, Medical Professionals, Pharmaceutical Marketing, Health Systems, Telehealth, AI, Physician Network, SEC Filing, 10-Q, Quarterly Earnings